Literature DB >> 12838271

Differential effects of within-day continuous vs. transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats.

Peter Turrone1, Gary Remington, Shitij Kapur, José N Nobrega.   

Abstract

Accumulating evidence suggests that antipsychotics (APs) that lead to sustained blockade of dopamine D(2) receptors are more likely to induce acute extrapyramidal side effects (EPS) compared to APs that only occupy D(2) receptors transiently. It is unclear, however, whether a similar relationship exists for long-term AP-induced motoric side effects like tardive dyskinesia (TD). The objective of this study was to ascertain whether transient (via daily subcutaneous (s.c.) injections) vs continuous (via osmotic minipump) AP-induced D(2) receptor occupancy differentially affects the development of haloperidol-induced vacuous chewing movements (VCMs), an animal model of TD. Six groups of 12 rats received 0.1, 0.25, or 1 mg/kg of haloperidol or vehicle (n=36) via osmotic minipump (to provide within-day sustained) or daily s.c. injection (within-day transient) for 8 weeks. VCMs were measured on a weekly basis and D(2) occupancy levels were measured in vivo using [(3)H]-raclopride at the end of the experiment. Minipump-treated rats developed HAL dose-dependent D(2) occupancies of 0.1 mg/kg/day (57%), 0.25 mg/kg/day (70%), and 1 mg/kg/day (88%). S.C.-treated rats also developed HAL dose-dependent D(2) occupancies of 0.1 mg/kg/day (83% peak, 3% trough), 0.25 mg/kg/day (89% peak, 0% trough), and 1 mg/kg/day (94% peak, 17% trough). A total of 43% of rats given 0.25 and 1 mg/kg/day of HAL via minipump developed high VCMs compared to only 8% of the rats given the same doses via daily s.c. injections. The 0.1 mg/kg dose did not give rise to VCMs beyond vehicle levels regardless of the route of administration. These findings support the contention that D(2) occupancy levels induced by chronic HAL must be high and sustained through the day before significant risk of VCMs, and perhaps also TD, emerges.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12838271     DOI: 10.1038/sj.npp.1300233

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  17 in total

Review 1.  Antipsychotic dosing: how much but also how often?

Authors:  Gary Remington; Shitij Kapur
Journal:  Schizophr Bull       Date:  2010-07-21       Impact factor: 9.306

Review 2.  Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.

Authors:  Anja Cerovecki; Richard Musil; Ansgar Klimke; Florian Seemüller; Ekkehard Haen; Rebecca Schennach; Kai-Uwe Kühn; Hans-Peter Volz; Michael Riedel
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

Review 3.  Oxidative stress and the antipsychotic-induced vacuous chewing movement model of tardive dyskinesia: evidence for antioxidant-based prevention strategies.

Authors:  Josh Lister; José N Nobrega; Paul J Fletcher; Gary Remington
Journal:  Psychopharmacology (Berl)       Date:  2014-04-22       Impact factor: 4.530

Review 4.  Antipsychotic dosing: found in translation.

Authors:  Gary Remington; Gagan Fervaha; George Foussias; Ofer Agid; Peter Turrone
Journal:  J Psychiatry Neurosci       Date:  2014-07       Impact factor: 6.186

5.  Pharmacologic rescue of motivational deficit in an animal model of the negative symptoms of schizophrenia.

Authors:  Eleanor H Simpson; Christoph Kellendonk; Ryan D Ward; Vanessa Richards; Olga Lipatova; Stephen Fairhurst; Eric R Kandel; Peter D Balsam
Journal:  Biol Psychiatry       Date:  2011-03-16       Impact factor: 13.382

6.  Contribution of decreased serotonin release to the antidyskinetic effects of deep brain stimulation in a rodent model of tardive dyskinesia: comparison of the subthalamic and entopeduncular nuclei.

Authors:  Meaghan C Creed; Clement Hamani; Alanna Bridgman; Paul J Fletcher; José N Nobrega
Journal:  J Neurosci       Date:  2012-07-11       Impact factor: 6.167

7.  Enhanced 5-HT2C receptor signaling is associated with haloperidol-induced "early onset" vacuous chewing in rats: implications for antipsychotic drug therapy.

Authors:  William A Wolf; Gerald J Bieganski; Veronica Guillen; Laurence Mignon
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

8.  Schizophrenia, amphetamine-induced sensitized state and acute amphetamine exposure all show a common alteration: increased dopamine D2 receptor dimerization.

Authors:  Min Wang; Lin Pei; Paul J Fletcher; Shitij Kapur; Philip Seeman; Fang Liu
Journal:  Mol Brain       Date:  2010-09-02       Impact factor: 4.041

9.  Quantitative mass spectrometry reveals changes in SNAP-25 isoforms in schizophrenia.

Authors:  Vilte E Barakauskas; Annie Moradian; Alasdair M Barr; Clare L Beasley; Gorazd Rosoklija; J John Mann; Boro Ilievski; Aleksandar Stankov; Andrew J Dwork; Peter Falkai; Gregg B Morin; William G Honer
Journal:  Schizophr Res       Date:  2016-03-09       Impact factor: 4.939

10.  Ilex paraguariensis has antioxidant potential and attenuates haloperidol-induced orofacial dyskinesia and memory dysfunction in rats.

Authors:  G Colpo; F Trevisol; A M Teixeira; R Fachinetto; R P Pereira; M L Athayde; J B T Rocha; M E Burger
Journal:  Neurotox Res       Date:  2007-10       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.